Johnson & Johnson has agreed to pay an undisclosed amount to settle a large number of lawsuits pending in a multidistrict litigation in New Jersey accusing the company’s diabetes drug Invokana of causing kidney failure, diabetic ketoacidosis or amputations, according to the New Jersey Law Journal. A settlement fund is expected to be ruled on by Nov. 19.
It’s unclear how many of the more than 1,000 cases are included in the settlement, but attorneys say more settlements are likely. Bellwethers from the multidistrict litigation were set to go to trial as early as January 2019, but those orders were vacated in May.
In August, discovery in the litigation was stayed until Oct. 30 “in light of the tremendous efforts of the parties to achieve resolution for the various injuries claimed in this complicated multidistrict litigation,” U.S. District Judge Brian Martinotti said.
Additional cases involving Invokana side effects are pending in state courts in Pennsylvania, California and New Jersey. Johnson & Johnson also faces Invokana class actions in Canada.
Invokana contains the drug ingredient canagliflozin from a drug class known as SGLT2 inhibitors. The drug is manufactured by Johnson & Johnson’s unit Janssen Pharmaceuticals. Invokana was approved by the Food and Drug Administration (FDA) in March 2013 to treat type 2 diabetes in adults. The following year, the company obtained approval for Invokamet, a combination of canagliflozin and the diabetes drug metformin. The lawsuits involve both Invokana and Invokamet.
In the years since its clearance, the FDA has issued warnings for Invokana and Invokamet involving kidney injury, ketoacidosis, serious bladder and kidney infections, and amputations.
Source: New Jersey Law Journal